GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

L. Pizzuti, D. Sergi, C. Mandoj, B. Antoniani, F. Sperati, A. Chirico, L. Di Lauro, M. Valle, A. Garofalo, E. Vizza, G. Corrado, F. Tomao, M. Rinaldi, S. Carpano, M. Maugeri-Sacca, L. Conti, G. Digiesi, P. Marchetti, R. De Maria, A. Giordano & 3 others M. Barba, M. A. Carosi, P. Vici

Research output: Contribution to journalArticle

Abstract

In recent years, the poorly remarkable goals achieved in terms of patients' important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 microm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.
Original languageEnglish
Pages (from-to)1396-1401
Number of pages6
JournalJournal of Cellular Physiology
Volume233
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Ovarian Neoplasms
Fasting
Glucose
Staining and Labeling
Biomarkers
Facilitative Glucose Transport Proteins
Energy Metabolism
Cell Membrane
Antibodies
Serum
Research
Neoplasms

Cite this

Pizzuti, L., Sergi, D., Mandoj, C., Antoniani, B., Sperati, F., Chirico, A., ... Vici, P. (2018). GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. Journal of Cellular Physiology, 233(2), 1396-1401. https://doi.org/10.1002/jcp.26023 [doi]

GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. / Pizzuti, L.; Sergi, D.; Mandoj, C.; Antoniani, B.; Sperati, F.; Chirico, A.; Lauro, L. Di; Valle, M.; Garofalo, A.; Vizza, E.; Corrado, G.; Tomao, F.; Rinaldi, M.; Carpano, S.; Maugeri-Sacca, M.; Conti, L.; Digiesi, G.; Marchetti, P.; Maria, R. De; Giordano, A.; Barba, M.; Carosi, M. A.; Vici, P.

In: Journal of Cellular Physiology, Vol. 233, No. 2, 01.02.2018, p. 1396-1401.

Research output: Contribution to journalArticle

Pizzuti, L, Sergi, D, Mandoj, C, Antoniani, B, Sperati, F, Chirico, A, Lauro, LD, Valle, M, Garofalo, A, Vizza, E, Corrado, G, Tomao, F, Rinaldi, M, Carpano, S, Maugeri-Sacca, M, Conti, L, Digiesi, G, Marchetti, P, Maria, RD, Giordano, A, Barba, M, Carosi, MA & Vici, P 2018, 'GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer', Journal of Cellular Physiology, vol. 233, no. 2, pp. 1396-1401. https://doi.org/10.1002/jcp.26023 [doi]
Pizzuti, L. ; Sergi, D. ; Mandoj, C. ; Antoniani, B. ; Sperati, F. ; Chirico, A. ; Lauro, L. Di ; Valle, M. ; Garofalo, A. ; Vizza, E. ; Corrado, G. ; Tomao, F. ; Rinaldi, M. ; Carpano, S. ; Maugeri-Sacca, M. ; Conti, L. ; Digiesi, G. ; Marchetti, P. ; Maria, R. De ; Giordano, A. ; Barba, M. ; Carosi, M. A. ; Vici, P. / GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. In: Journal of Cellular Physiology. 2018 ; Vol. 233, No. 2. pp. 1396-1401.
@article{7948d72e27834c1cb998e767befb4f0b,
title = "GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer",
abstract = "In recent years, the poorly remarkable goals achieved in terms of patients' important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 microm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5{\%}) of them. The agreement between the two independent reviewers was 100{\%}. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.",
author = "L. Pizzuti and D. Sergi and C. Mandoj and B. Antoniani and F. Sperati and A. Chirico and Lauro, {L. Di} and M. Valle and A. Garofalo and E. Vizza and G. Corrado and F. Tomao and M. Rinaldi and S. Carpano and M. Maugeri-Sacca and L. Conti and G. Digiesi and P. Marchetti and Maria, {R. De} and A. Giordano and M. Barba and Carosi, {M. A.} and P. Vici",
note = "LR: 20171128; CI: (c) 2017; JID: 0050222; 0 (Biomarkers, Tumor); 0 (Blood Glucose); 0 (Glucose Transporter Type 1); 0 (SLC2A1 protein, human); OTO: NOTNLM; 2017/05/19 00:00 [received]; 2017/05/19 00:00 [accepted]; 2017/05/26 06:00 [pubmed]; 2017/11/29 06:00 [medline]; 2017/05/26 06:00 [entrez]; ppublish",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/jcp.26023 [doi]",
language = "English",
volume = "233",
pages = "1396--1401",
journal = "Journal of Cellular Physiology",
issn = "1097-4652",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer

AU - Pizzuti, L.

AU - Sergi, D.

AU - Mandoj, C.

AU - Antoniani, B.

AU - Sperati, F.

AU - Chirico, A.

AU - Lauro, L. Di

AU - Valle, M.

AU - Garofalo, A.

AU - Vizza, E.

AU - Corrado, G.

AU - Tomao, F.

AU - Rinaldi, M.

AU - Carpano, S.

AU - Maugeri-Sacca, M.

AU - Conti, L.

AU - Digiesi, G.

AU - Marchetti, P.

AU - Maria, R. De

AU - Giordano, A.

AU - Barba, M.

AU - Carosi, M. A.

AU - Vici, P.

N1 - LR: 20171128; CI: (c) 2017; JID: 0050222; 0 (Biomarkers, Tumor); 0 (Blood Glucose); 0 (Glucose Transporter Type 1); 0 (SLC2A1 protein, human); OTO: NOTNLM; 2017/05/19 00:00 [received]; 2017/05/19 00:00 [accepted]; 2017/05/26 06:00 [pubmed]; 2017/11/29 06:00 [medline]; 2017/05/26 06:00 [entrez]; ppublish

PY - 2018/2/1

Y1 - 2018/2/1

N2 - In recent years, the poorly remarkable goals achieved in terms of patients' important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 microm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.

AB - In recent years, the poorly remarkable goals achieved in terms of patients' important outcomes for ovarian cancer have fueled our interest toward the study of its metabolic roots. Within this research pipeline, we assessed the association between the expression of the glucose transporter GLUT1, as expressed at the tumor tissue level, and circulating pre-surgical levels of fasting glucose in a case series including data from 40 patients with high FIGO stage serous ovarian cancer. Patients who provided data to the current analysis were randomly selected from a larger cohort. To our purposes, the procedures related to serum and tissue collection, storage and biomarker assessment were highly standardized and centralized at the institutional laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 1:500 dilution in 2 microm slides. Staining for GLUT1 was observed at the cell membrane level in all the cases assessed, but strong staining was described in 29 (72.5%) of them. The agreement between the two independent reviewers was 100%. Strong GLUT1 staining was inversely associated with circulating levels of fasting glucose, with a particularly striking difference for patients in the lowest fasting glucose tertile (p = 0.044). These results support the biological plausibility of the association of interest. If confirmed in larger studies, our findings may help clarify the potentials of biomarkers related to energy metabolism in terms of prognosis definition, treatment assignment, and outcome interpretation for patients with high FIGO stage serous ovarian cancer.

U2 - 10.1002/jcp.26023 [doi]

DO - 10.1002/jcp.26023 [doi]

M3 - Article

VL - 233

SP - 1396

EP - 1401

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 1097-4652

IS - 2

ER -